Compare GCO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | EDIT |
|---|---|---|
| Founded | 1924 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.1M | 368.6M |
| IPO Year | 1994 | 2016 |
| Metric | GCO | EDIT |
|---|---|---|
| Price | $36.39 | $2.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $39.67 | $6.10 |
| AVG Volume (30 Days) | 104.9K | ★ 2.3M |
| Earning Date | 12-03-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.84 | 37.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,606,898,000.00 | $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.71 | ★ 132.64 |
| 52 Week Low | $21.93 | $1.66 |
| 52 Week High | $43.60 | $3.94 |
| Indicator | GCO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 65.21 | 53.10 |
| Support Level | $31.83 | $2.65 |
| Resistance Level | $43.60 | $2.77 |
| Average True Range (ATR) | 1.30 | 0.19 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 85.26 | 66.20 |
Genesco Inc sells footwear, headwear, sports apparel, and accessories. It has four reportable business segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass. The brands of the company are: Journeys; Journeys Kidz; Little Burgundy; Schuh; Johnston & Murphy; and Genesco Brands Group.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.